Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
作者信息
Carrot-Zhang Jian, Yao Xiaotong, Devarakonda Siddhartha, Deshpande Aditya, Damrauer Jeffrey S, Silva Tiago Chedraoui, Wong Christopher K, Choi Hyo Young, Felau Ina, Robertson A Gordon, Castro Mauro A A, Bao Lisui, Rheinbay Esther, Liu Eric Minwei, Trieu Tuan, Haan David, Yau Christina, Hinoue Toshinori, Liu Yuexin, Shapira Ofer, Kumar Kiran, Mungall Karen L, Zhang Hailei, June-Koo Lee Jake, Berger Ashton, Gao Galen F, Zhitomirsky Binyamin, Liang Wen-Wei, Zhou Meng, Moorthi Sitapriya, Berger Alice H, Collisson Eric A, Zody Michael C, Ding Li, Cherniack Andrew D, Getz Gad, Elemento Olivier, Benz Christopher C, Stuart Josh, Zenklusen J C, Beroukhim Rameen, Chang Jason C, Campbell Joshua D, Hayes D Neil, Yang Lixing, Laird Peter W, Weinstein John N, Kwiatkowski David J, Tsao Ming S, Travis William D, Khurana Ekta, Berman Benjamin P, Hoadley Katherine A, Robine Nicolas, Meyerson Matthew, Govindan Ramaswamy, Imielinski Marcin
出版信息
Cell Rep. 2021 Feb 23;34(8):108784. doi: 10.1016/j.celrep.2021.108784.
Abstract
摘要
相似文献
1
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Cell Rep. 2021 Feb 23;34(8):108784. doi: 10.1016/j.celrep.2021.108784.
2
Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.
Cell Rep. 2021 Feb 2;34(5):108707. doi: 10.1016/j.celrep.2021.108707.
3
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Mol Cancer Res. 2016 Mar;14(3):296-301. doi: 10.1158/1541-7786.MCR-15-0392-T. Epub 2015 Dec 11.
4
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.
Semin Cancer Biol. 2019 Feb;54:14-28. doi: 10.1016/j.semcancer.2017.11.016. Epub 2017 Nov 22.
5
Identification and Characterization of Oncogenic Mutations in Lung Adenocarcinoma.
Mol Cancer Res. 2019 Apr;17(4):1002-1012. doi: 10.1158/1541-7786.MCR-18-0316. Epub 2019 Jan 11.
6
Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
Int J Cancer. 2022 Dec 1;151(11):2020-2030. doi: 10.1002/ijc.34238. Epub 2022 Aug 27.
7
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.
8
Pathway Alterations in Stage II/III Primary Melanoma.
JCO Precis Oncol. 2023 Mar;7:e2200439. doi: 10.1200/PO.22.00439.
9
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Virchows Arch. 2006 Jun;448(6):788-96. doi: 10.1007/s00428-006-0191-8. Epub 2006 Apr 6.
10
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9.
引用本文的文献
1
Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma.
Mol Cell. 2025 Apr 3;85(7):1311-1329.e16. doi: 10.1016/j.molcel.2025.03.001. Epub 2025 Mar 25.
2
The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer.
ESMO Open. 2025 Apr;10(4):104479. doi: 10.1016/j.esmoop.2025.104479. Epub 2025 Mar 14.
3
Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma.
Cancer Immunol Immunother. 2025 Mar 3;74(4):131. doi: 10.1007/s00262-025-03972-x.
4
Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases.
Biochem Soc Trans. 2024 Oct 30;52(5):2193-2201. doi: 10.1042/BST20240242.
5
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
Mol Cancer. 2024 Jun 11;23(1):126. doi: 10.1186/s12943-024-02035-6.
6
Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer.
Oncol Lett. 2024 Apr 9;27(6):259. doi: 10.3892/ol.2024.14392. eCollection 2024 Jun.
7
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Oncologist. 2024 Aug 5;29(8):e984-e996. doi: 10.1093/oncolo/oyae028.
8
Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men.
iScience. 2024 Jan 11;27(2):108858. doi: 10.1016/j.isci.2024.108858. eCollection 2024 Feb 16.
9
Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma.
BMJ Open Respir Res. 2023 Dec 11;10(1):e001878. doi: 10.1136/bmjresp-2023-001878.
10
Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Sci Rep. 2023 Nov 27;13(1):20930. doi: 10.1038/s41598-023-47659-8.
Zotero 插件